Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01863199 · ClinicalTrials.gov registry record · Phase 4
Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)
A Phase 4 study of Neovascular Age-related Macular Degeneration, sponsored by Retinal Consultants of Arizona.
- Completed
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
- 4
- Study locations
NCT01863199 is a Phase 4 study of Neovascular Age-related Macular Degeneration that has completed, run by Retinal Consultants of Arizona. The registered enrollment target is 60 participants, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (85% lower). The trial reports 4 study locations across 1 state.
The verdict
NCT01863199, a Phase 4 study of Neovascular Age-related Macular Degeneration, has completed, sponsored by Retinal Consultants of Arizona.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
- 4
- Study locations
Study Summary
A study to use in home technology to reduce the burden of in office visits and injections.
Conditions Studied
Interventions
- DRUG Lucentis (Treat and extend)
- DRUG Lucentis every 4 weeks
- DRUG Lucentis every 12 weeks
Study Locations (4)
Arizona
- Retinal Consultants of Arizona - Gilbert
- Retinal Consultants of Arizona - Mesa
- Retinal Consultants of Arizona - Peoria
- Retinal Consultants of Arizona - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01863199
The ClinicalTrials.gov registry entry for NCT01863199 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 407-participant average among 33 other Neovascular Age-related Macular Degeneration trials with a reported enrollment target (85% lower). The listed sponsor is Retinal Consultants of Arizona, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Neovascular Age-related Macular Degeneration appearing as the primary indexed condition, and to 3 interventions - of which Lucentis (Treat and extend) is the first listed.
NCT01863199 reports 4 study locations spanning 1 distinct geographic area - top geographies include Arizona.
Frequently Asked Questions
What is clinical trial NCT01863199 about?
NCT01863199 is a clinical study titled "Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)". A study to use in home technology to reduce the burden of in office visits and injections.
What is the current status of trial NCT01863199?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2013-05. Estimated completion is 2015-12.
What conditions does trial NCT01863199 study?
This clinical trial studies the following conditions: Neovascular Age-related Macular Degeneration.
What interventions are being tested in trial NCT01863199?
The interventions under investigation include: Lucentis (Treat and extend) (DRUG), Lucentis every 4 weeks (DRUG), Lucentis every 12 weeks (DRUG).
Who is sponsoring clinical trial NCT01863199?
This trial is sponsored by Retinal Consultants of Arizona, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01863199 being conducted?
This trial has 4 study locations across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neovascular Age-related Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
RECRUITING · Phase 4
-
Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
RECRUITING · Phase 1
-
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
RECRUITING · Phase 3
-
A Safety and Efficacy Study of One-time SAR402663 in Adults With Neovascular Age-related Macular Degeneration
RECRUITING · Phase 1
-
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
RECRUITING · Phase 3
-
Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMD
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.